GNI Group

2160.TSE

16.96 USD

0.15

+0.89%

Overview

Last close

16.96 usd

Market cap

851.34M usd

52 week high

25.86 usd

52 week low

10.22 usd

Target price

26.37 usd

Valuation

P/E

118.1259

Forward P/E

N/A

Price/Sales

5.3075

Price/Book Value

3.2703

Enterprise Value

732.71M usd

EV/Revenue

4.5313

EV/EBITDA

34.4904

Key financials

Revenue TTM

161.70M usd

Gross Profit TTM

123.52M usd

EBITDA TTM

17.41M usd

Earnings per Share

0.14 usd

Dividend

N/A usd

Total assets

447.52M usd

Net debt

-18.61M usd

About

GNI Group Ltd. engages in the research, development, manufacture, and sale of pharmaceutical drugs in Japan and internationally. The company offers Etuary for the treatment of idiopathic pulmonary fibrosis. It also developing Etuary, which is in Phase III clinical trial for the treatment of connective tissue associated interstitial lung disease; and in clinical trial pre-phase III clinical trial pilot study for the treatment of radiation pneumonitis, as well as for the treatment of diabetic nephropathy. In addition, the company involved in developing F351, which is in Phase III clinical trial for the treatment of liver fibrosis; and F573 that is in phase II for the treatment of acute on chronic liver failure, as well as Tamibarotene for the treatment of acute promyelocytic leukemia. GNI Group Ltd. was incorporated in 2001 and is headquartered in Tokyo, Japan.